Eric Salzman is the Chief Executive Officer of publicly traded Safeguard Scientifics, which provides capital and relevant expertise to fuel the growth of technology-driven businesses in healthcare, financial services, and digital media. Eric was appointed CEO in October 2020 and currently represents Safeguard on the boards of Aktana, Infobionic, meQuilibrium, Prognos, Syapse, Trice Medical, and Clutch.
For more than 25 years, Eric has helped technology focused companies drive growth and navigate major periods of transformation, leading the implementation of strategic operating plans, corporate finance transactions and M&A. He has served as executive chairman, non-executive chairman, special committee chair and independent director at more than 25 public and private companies including portfolio companies of Ares, Athyrium, Blackstone, Carlyle, Francisco Partners and KKR. Presently, Eric also serves as an independent director, Chairman of the Compensation Committee, and member of the Audit Committee at publicly traded 8×8, Inc.
Earlier in his career, Eric spent nearly ten years employed by Lehman Brothers as a Managing Director in the Private Equity and Principal Investing Group as well as a Managing Director in the Global Trading Strategies Division. Eric earned a B.A. Honors from the University of Michigan and an MBA from Harvard University.